Henry A. Palmer CE Finale, LIVE December 19, 2025

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Statements of credit for the online activities:

ACPE UAN 0009-0000-25-062-L03-P

ACPE UAN 0009-0000-25-063-L99-P

ACPE UAN 0009-0000-25-064-L01-P

ACPE UAN 0009-0000-25-065-L01-P

ACPE UAN 0009-0000-25-066-L05-P

ACPE UAN 0009-0000-25-067-L01-P

ACPE UAN 0009-0000-25-068-L01-P

ACPE UAN 0009-0000-25-069-L06-P

- will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

Jeannette Y. Wick, RPh, MBA, Director of the Office of Professional Pharmacy Development, University of Connecticut School of Pharmacy, Storrs, CT

Jennifer Luciano, PharmD, Director of Office of Experiential Education, University of Connecticut School of Pharmacy, Storrs, CT

William L. Baker, PharmD, FCCP, FACC, FHFSA, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

Devra Dang, PharmD, CDCES, FNAP, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

Michael White, PharmD, FCP, FCCP, FASHP, Distinguished Professor and Chair, Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT

Kelsey Giara, PharmD, University of Connecticut School of Pharmacy, Storrs, CT

Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

Jeff Aeschlimann, PharmD, University of Connecticut School of Pharmacy, Storrs, CT

HANDOUTS for Presentations

8:10 - 9:10 a.m. – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain

2 Slides per page

6 Slides per page

9:15 - 10:15 a.m. – Step by Step: Tackling Imposter Syndrome in Every Transition

2 Slides per page

6 Slides per page

10:20-11:20 a.m. – NKOTB: 2025 Updates on Management of Hypertension in Adults

2 Slides per page

6 Slides per page

11:25-12:25 p.m. - NKOTB: New and Emerging Roles for GLP-1-Based Medications

2 Slides per page color graphs

2 Slides per page black and white

6 Slides per page color graphs

6 Slides per page black and white

12:45-1:45 p.m. – PATIENT SAFETY: Biosimilar Doppelgangers

2 Slides per page

6 Slides per page

1:50-2:50 p.m. – Hormone Therapy’s Twin Faces: Sorting Science from Misconception

2 Slides per page

6 Slides per page

2:55-3:55 p.m. – Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block

2 Slides per page

6 Slides per page

4:00-5:00 p.m. – IMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025

2 Slides per page

6 Slides per page

7:30-8:00 a.m. - Registration and Check-In/Sign-In

8:00-8:05 a.m. - Opening Remarks- Philip M. Hritcko, Dean and Clinical Professor, University of Connecticut School of Pharmacy

8:05-8:10 a.m. – Operational Instructions- Jeannette Y. Wick, RPh, MBA, Director of the Office of Professional Pharmacy Development, University of Connecticut School of Pharmacy, Storrs, CT

8:10 - 9:10 a.m. – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain

Jeannette Y. Wick, RPh, MBA, Director of the Office of Professional Pharmacy Development, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-062-L03-P (0.1 CEU or 1 contact hour) (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Define the terms “counterfeit” and "spurious" drugs
Discuss the prevalence of counterfeiting globally and in the United States
List factors that contribute to drug counterfeiting
Discuss the Drug Supply Chain Security Act (DSCSA) and its implications for the drug supply distribution chain’s integrity
Identify steps that reduce the risk of suspect product being delivered to the pharmacy and to patients

9:15 - 10:15 a.m. – Step by Step: Tackling Imposter Syndrome in Every Transition

Jennifer Luciano, PharmD, Director of Office of Experiential Education, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-063-L99-P (0.1 CEU or 1 contact hour) (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Recognize the signs and symptoms of imposter syndrome as they commonly present in pharmacy practice and education, including during career transitions such as rotations, residency, and new professional roles
Examine the personal, academic, and systemic factors that contribute to imposter syndrome among pharmacists and pharmacy students, with emphasis on high-performance expectations and professional identity formation
Identify practical, evidence-based strategies to manage and overcome imposter syndrome, fostering resilience, confidence, and professional growth within pharmacy practice and education

10:20-11:20 a.m. – NKOTB: 2025 Updates on Management of Hypertension in Adults

William L. Baker, PharmD, FCCP, FACC, FHFSA, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-064-L01-P (0.1 CEU or 1 contact hour) (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Review the 2025 hypertension guidelines
Compare the updated recommendations to the prior guidelines
Review the evidence supporting the guideline changes

11:25-12:25 p.m. - NKOTB: New and Emerging Roles for GLP-1-Based Medications

Devra Dang, PharmD, CDCES, FNAP, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-065-L01-P (0.1 CEU or 1 contact hour) (Knowledge-based)

At the conclusion of this presentation, pharmacists will be able to

List recent FDA-approved indications for GLP-1-based medications
Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease
Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications

12:25-12:45 p.m. – BREAK. Light snacks will be served.

12:45-1:45 p.m. – PATIENT SAFETY: Biosimilar Doppelgangers

Michael White, PharmD, FCP, FCCP, FASHP, Distinguished Professor and Chair, Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-066-L05-P (0.1 CEU or 1 contact hour) (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Compare and contrast a small molecule drug from a biological drug
Compare and contrast how a reference biologic drug compares with its biosimilar
Describe where a pharmacist would identify a biosimilar product and the legal implications of a biosimilar achieving interchangeable status with a reference product
Describe the nocebo effect and how to prevent it from occurring
Apply the knowledge from the objectives above to specific patient care scenarios in the self-assessment questions

1:50-2:50 p.m. – Hormone Therapy’s Twin Faces: Sorting Science from Misconception

Kelsey Giara, PharmD, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-067-L01-P (0.1 CEU or 1 contact hour (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Discuss the clinical evidence on safety, efficacy, and patient outcomes for hormone replacement therapy (HRT), highlighting areas of misconception or confusion
Compare HRT options and bioidenticals, including mechanisms of action, formulations, and regulatory pathways
Apply guidelines and evidence-based recommendations to individualize patient counseling and therapeutic decision-making when managing HRT

2:55-3:55 p.m. – Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block

Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-068-L01-P (0.1 CEU or 1 contact hour) (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Describe the unique mechanisms of action of xanomeline-trospium in the management of schizophrenia and dextromethorphan-containing medications in the management of major depressive disorder
Distinguish between adverse effect profiles of new psychiatric medications compared to traditional antipsychotics and antidepressants
Identify appropriate candidates for new psychiatric medications based on knowledge of efficacy, safety, and patient-specific factors

4:00-5:00 p.m. – IMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025

Jeff Aeschlimann, PharmD, University of Connecticut School of Pharmacy, Storrs, CT

0009-0000-25-069-L06-P (0.1 CEU or 1 contact hour) (Application-based)

At the conclusion of this presentation, pharmacists will be able to

Describe at least one important change (or proposed change) in childhood and adult vaccination recommendations put forth by the CDC and/or ACIP
Given a patient who asks about receiving respiratory virus or bacteria vaccinations (e.g., Influenza, COVID-19, respiratory syncytial virus (RSV), pneumococcal), outline important differences between multiple products when they exist
Identify evidence-based pharmacotherapeutic treatments for common vaccine-preventable illnesses

CE FINALE LIVE ENCORE WEBINARS AVAILABLE

If you find you cannot make it to our LIVE EVENT on Friday, December 19^th, you can participate in our ENCORE LIVE WEBINARS that will be streamed on the following dates:

Monday, December 22, 12:00 (Noon) - 1:00 pm – NKOTB: New and Emerging Roles for GLP-1-Based Medications
Monday, December 22, 7:00 pm-8:00 pm – Hormone Therapy’s Twin Faces: Sorting Science from Misconception
Monday, December 22, 8:10 – 9:10 pm – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain
Tuesday, December 23, 12:00 pm-1:00 pm – PATIENT SAFETY: Biosimilar Doppelgangers
Tuesday, December 23, 7 pm – 8 pm – IMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025
Monday, December 29, 12:00 (Noon) – 1:00 pm - Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block
Monday, December 29, 7 pm – 8 pm – LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain
Tuesday, December 30, 12:00 (Noon) – 1:00 pm - NKOTB: 2025 Updates on Management of Hypertension in Adults
Tuesday, December 30, 7 pm – 8 pm - Step by Step: Tackling Imposter Syndrome in Every Transition

A continuous class schedule format will be used. This format does not include breaks but does include a 20-minute lunch period. Activities on December 19^th cost $60 for the first hour. Each additional activity costs $20. Early bird pricing ends December 15, 2025. Starting December 16, $25 is added to the total.

Refunds and Cancellations: The registration fee, less a $75 processing fee, is refundable for those who cancel their registration three (3) days prior to the program (by December 16) After that time, no refund is available.

Location: The Henry A. Palmer C.E. Finale will be held both virtually and in-person. You must sign in to the Webex link at the designated time using the link in your confirmation email if you decide to participate virtually.

Continuing Education Units

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 8 contact hours (0.80 CEU) one of which is a law credit, one is an Immunization Credit, and one is a Patient Safety Credit.

Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (before February 1, 2026). Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with Heather.Kleven@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to ensure that your credits have been properly uploaded. Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

Our paper check processing system is quite slow. Please contact Heather.Kleven@uconn.edu if you must pay by check.

Registration Fees: 50% discount for UConn faculty/preceptors

Step by Step: Tackling Imposter Syndrome in Every Transition – RECORDED WEBINAR

Learning Objectives

Recognize the signs and symptoms of imposter syndrome as they commonly present in pharmacy practice and education, including during career transitions such as rotations, residency, and new professional roles

Examine the personal, academic, and systemic factors that contribute to imposter syndrome among pharmacists and pharmacy students, with emphasis on high-performance expectations and professional identity formation

Identify practical, evidence-based strategies to manage and overcome imposter syndrome, fostering resilience, confidence, and professional growth within pharmacy practice and education

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour for completing the activity (ACPE UAN 0009-0000-25-063-H99-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

1. During her first advanced pharmacy practice experience (APPE) rotation, Taylor believes her success is due to luck and fears being “exposed” as incompetent. Which of the following signs BEST indicates Taylor may be experiencing imposter syndrome?

She frequently attributes her achievements to external factors rather than her own skills
She seeks constructive feedback to improve her clinical performance
She feels confident in her abilities after receiving positive evaluations

2. Samantha, a third-year pharmacy student, feels constant pressure to maintain perfect grades and outperform her peers. Which factor MOST likely contributes to her imposter syndrome?

Lack of interest in clinical practice
Limited exposure to patient care settings
High-performance expectations within pharmacy education

3. Jonathan, a fourth-year pharmacy student, received an award for academic excellence but feels it was only due to luck. Which cognitive reframing technique would BEST help Jonathan?

Avoid taking on challenging cases to reduce the risk of failure
Ignore his feelings and focus solely on upcoming tasks
Challenge negative thoughts by listing specific actions that led to his success

4. Alex feels anxious before a case presentation and believes others are more knowledgeable. Which strategy would MOST helpful?

Memorize every detail to avoid mistakes.
Practice self-compassion and remind himself learning is a process.
Compare his style to the top-performing student.

5. A new clinical pharmacist feels inadequate despite meeting all performance metrics. She attributes her success to luck and fears her colleagues will discover she isn’t qualified. Which combination of factors MOST likely contributes to her imposter syndrome?

Personal perfectionism, competitive academic background, and systemic emphasis on error-free practice
Lack of interest in patient care, minimal training, and supportive work environment
Strong mentorship, realistic expectations, and collaborative culture

6. During a clinical skills lab, Jordan, a third-year pharmacy student, feels overwhelmed and believes he is the only one struggling. Which of the following group-based strategies would BEST help Jordan reduce imposter feelings?

Compare his performance to the highest-scoring student for motivation
Participate in peer discussions to normalize challenges and share experiences
Volunteer for extra tasks to prove his competence

NKOTB: 2025 Updates on Management of Hypertension in Adults – RECORDED WEBINAR

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour for completing the activity (ACPE UAN 0009-0000-25-064-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

According to the 2025 guidelines, which of the following represents the blood pressure goal for adults with confirmed hypertension?
1. SBP < 120 mmHg & DBP < 70 mmHg
2. SBP < 130 mmHg & DBP < 80 mmHg
3. SBP < 140 mmHg & DBP < 90 mmHg
According to the 2025 Hypertension guidelines, which of the following would be an appropriate initial combination to start in a patient with stage 2 hypertension?
1. Lisinopril + amlodipine***
2. Valsartan + chlorthalidone
3. Verapamil + hydrochlorothiazide
When using the PREVENT equation to estimate 10-year cardiovascular disease risk, what is the threshold above which a patient with hypertension should be initiated on drug therapy medications to lower their blood pressure?
1. >5%
2. >7.5%
3. >10%
Which of the following represents a new recommendation in the 2025 Hypertension guideline that was not in the previous (2017) version?
1. Start initial combination therapy for anyone with stage 2 hypertension
2. ACEi/ARB, CCB, and diuretics are first-line therapies unless contraindicated
3. Individuals without BP ≥130/80 mmHg, no CVD, and a 10-year CVD risk ≥7.5% should start antihypertensive medication
Which of the following is most accurate about emerging drug treatments for hypertension?
1. Emerging drug therapies, while effective, have concerns for hyperkalemia and hypotension
2. Trials have exclusively been conducted in newly-diagnosed adult patients
3. Mechanisms of emerging drugs have targeted attenuation of the sympathetic nervous system

Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults – RECORDED WEBINAR

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-047-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Immunization: Our Best Shot - Tips and Tools to Vaccinate Older Adults

After completing this continuing education activity, pharmacists will be able to

• Recognize appropriate vaccine recommendations for the older adult population
• Identify potential barriers to vaccinations
• Analyze current methods used to improve vaccination rates
• Discuss ways to improve vaccine compliance in your patient population

1. How many vaccines does the CDC strongly recommend for older adults?
a. Just two: influenza and COVID
b. Three: influenza, COVID, and RSV
c. Six-ish!!! (It depends)

2. New patient, ES, age 60, has recently moved to Connecticut from Ontario, Canada. The patient reports receiving Zostavax 1 month ago. Which of the following recommendations regarding the administration of Shingrix is correct?
a. Shingrix is contraindicated in those who have received Zostavax.
b. It is recommended to administer the Shingrix vaccine immediately.
c. It is recommended to wait at least 8 weeks after receiving Zostavax.

3. Which of the following situations might act as a barrier to vaccine uptake in older adults?
a. The nearest pharmacy and healthcare facilities are miles away and not on a bus route.
b. Other people at the senior center have had COVID, the flu, or shingles recently and been quite ill.
c. Pharmacy staff asks pleasantly and often if they might be ready to be vaccinated.

4. Which of the following is an example of a contextual influence as defined by the Vaccine Hesitancy Determinants Matrix?
a. Personal experience with vaccinations
b. Communication and media environment
c. Mode of vaccine administration

5. Which of these programs is a federal program that uses digital outreach, television, print, and radio to decrease vaccine hesitancy among older adults?
a. Risk Less, Do More
b. It’s a Sure Shot
c. No Shot in the Dark

6. You’re monitoring vaccine uptake in your community and it is alarmingly low. You decide to use the S-H-A-R-E method of encouraging vaccine uptake. What does the R stand for?
a. Remind patients that getting a vaccine-preventable disease is costly
b. Remind patients that vaccines protect them and their loved ones
c. Remind patients that you have the vaccines they need in stock

Share the tailored reasons why the recommended vaccine is right for the patient
Highlight positive experiences with vaccines (anecdotal or in practice) to strengthen confidence
Address patient questions and concerns about the vaccine
Remind patients that vaccines protect them and their loved ones
Explain the potential costs of getting the disease

Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia-RECORDED WEBINAR

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances

2. Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options

3. Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-048-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Waters is on the Johnson and Johnson speakers' bureau, but the information discussed here has no overlap. All financial relationships with ineligible companies have been mitigated.

Behavioral Symptoms of Dementia Assessment Questions

Which of the following is a symptom of agitation in dementia?

Hallucinations
Restless leg syndrome
Throwing objects

A 64-year-old patient has a PMH of AD, hypertension, urinary incontinence, and insomnia. Recently, they have been increasingly agitated throughout both the day and night. Symptoms primarily include pacing and verbally repeating the same phrases many times. Non-pharmacologic intervention is mildly effective, but the patient’s caregiver is requesting pharmacologic intervention as well.

Current medications:

Amlodipine 10 mg po daily

Oxybutynin 10 mg po daily

Diphenhydramine 25 mg po nightly prn insomnia

Cetirizine 10 mg po daily

Melatonin 6 mg po nightly Which of the following is the best first step in managing the patient’s agitation?

Discontinue melatonin
Reduce anticholinergic load
Reduce dose of amlodipine

3. The patient and caregiver agree to discontinuation of the cetirizine and diphenhydramine. They feel strongly that the oxybutynin improves their quality of life by allowing them to not become incontinent of urine overnight. Unfortunately, several weeks later the agitation symptoms persist. Which of the following is the best recommendations at this time?

a. Initiate citalopram

b. Initiate haloperidol

c. Initiate risperidone

A 71-year-old patient with vascular dementia recently started insisting that unknown people were living in his attic. He says he can hear the intruders talking during the night but they hide whenever someone goes up to check. The patient is extremely distressed about this and is trying to obtain a firearm to protect his family from these intruders.

Which of the following pharmacologic recommendations may be appropriate?

Brexpiprazole
Trazodone
Haloperidol

The patient’s symptoms improve significantly after starting brexpiprazole. However, he is still very restless at night and wakes up frequently. He reports being “exhausted” each day. Which of the following would be the best pharmacologic option?

Melatonin
Eszopiclone
Suvorexant

6. Which medication approved for Parkinson’s disease psychosis has demonstrated the ability to prolong time to relapse of psychosis in Alzheimer’s disease?

a. Brexpiprazole

b. Pimavanserin

c. Dexmedetomidine

7. Which of the following behavioral symptoms of dementia is the most common?

a. Apathy

b. Psychosis

c. Anxiety

Opioids: Impact of Palliative Care on Total Pain in the Older Adult-RECORDED WEBINAR

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-046-H08-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Opioids: Impact of Palliative Care on Total Pain in the Older Adult

Post Test Questions

Which of the following are goals of palliative care?
1. Convince patients to enroll with hospice for end-of-life care
2. Stop curative intent therapies to focus on comfort
3. Improve quality of life for patients and families

Which of the following is true regarding the differences between primary palliative care and specialty palliative care?
1. Any individual healthcare provider can provide primary palliative care
2. Primary palliative care always comes first
3. Specialty palliative care always requires insurance prior authorization

Which of the following is the IASP definition of pain?
1. An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage
2. An unpleasant physical experience associated with, or resembling that associated with, actual or potential tissue damage
3. An unpleasant emotional experience associated with, or resembling that associated with, actual tissue damage

Approximately how much money is spent annually via direct medical costs, lost productivity and disability related to chronic pain in the United States?
1. $5.6 billion
2. $56 billion
3. $560 billion

Which of the following pain types is defined as maladaptive changes in pain processing and modulation without evidence of tissue or nerve damage?
1. Nociceptive pain
2. Nociplastic pain
3. Neuropathic pain

Which of the following is the correct definition of “total pain”?
1. The total suffering of one’s physical, social, psychological and spiritual self that is experienced when dealing with serious illness
2. The total suffering of one’s physical, social, psychological and spiritual self that is experienced with first time home buying
3. The total suffering of one’s physical, social, psychological and spiritual self that is experienced when taking CE post-tests

How does non-physical pain and suffering often manifest?
1. Reports of worsening mood
2. Reports of physical pain
3. Reports of fear of dying

LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation RECORDED WEBINAR

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Explain common terminology associated with commercials targeting older Americans

2. Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm

3. Discuss generalities in potential lawsuits associated with media promotion campaigns

4. Identify areas where no information is available to provide good, valid answers for patients who ask questions

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-049-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

LAW: Call 1-800-Get-Cash Fast

After completing this continuing education activity, learners will be able to

Explain common terminology associated with commercials targeting older Americans
Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm
Discuss generalities in potential lawsuits associated with media promotion campaigns
Identify areas where no information is available to provide good, valid answers for patients who ask questions

What is the legal lingo for cases that are solicited on television using 1-800 numbers?

Class action suits
Torte claims
Product liability suits

What groups have traditionally been represented in parens patriae suits?
State residents who appeal to the state to represent them
Smokers and people who have opioid or alcohol use disorder
Children, the mentally ill, people who are legally incompetent

What is usury law?

Laws pertaining to the use of a commercial product that results in alleged harm to a group of people who become plaintiffs
Laws pertaining to lending money at an interest rate that is unreasonably high or higher than the rate permitted by law
Laws pertaining to any claim that arises in civil court, with the exception of contractual disputes, property, or criminal activity

When discussing multi-district litigation (MDL), what does the adjective “generic” mean?

It means that most torte claims do not include generic drugs; they focus on brand names
It means assets (documents, expert opinion, interviews, etc) that apply to all plaintiffs
It means developing charts, timelines, and visuals that a judge and jury will understand

A patient asks you if you can determine how much money he might get if he joins a multi-district litigation on ranitidine. What do you say?

Call the 1-800 number advertised on TV; the operator can provide that information.
Go to the local library and access LegalTrac; settlement amounts are tracked closely.
That information is guarded closely by nondisclosure agreements; it’s hard to tell.

What is the Texas Two-Step in the legal arena?
A term describing division of assets and liabilities between two companies
A term describing a non-opt-out settlement for mass tort liability
A term describing companies’ tendency to declare bankruptcy swiftly

In a case against a major pharmaceutical company that made a liquid cherry flavored gastroprokinetic drug for adults, who received the lion’s share of the settlement?

The patients/plaintiff
The attorneys
Others

Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block-RECORDED WEBINAR

Upon completion of this application based CE Activity, a pharmacist will be able to:

Describe the unique mechanisms of action of xanomeline-trospium in the management of schizophrenia and dextromethorphan-containing medications in the management of major depressive disorder
Distinguish between adverse effect profiles of new psychiatric medications compared to traditional antipsychotics and antidepressants
Identify appropriate candidates for new psychiatric medications based on knowledge of efficacy, safety, and patient-specific factors

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-25-068-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Dr. Waters is on the Johnson and Johnson speakers' bureau, but the information discussed here has no overlap. All financial relationships with ineligible companies have been mitigated.

NKOTB: Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block Assessment Questions

25-068

Posttest

What is the purpose of pairing trospium with xanomeline in the combination drug used in the management of schizophrenia?
1. 1. Trospium reduces the amount of weight gain associated with xanomeline.
  2. Trospium effectively treats the cognitive symptoms associated with schizophrenia.
  3. Trospium reduces the amount of gastrointestinal adverse effects associated with xanomeline.
Compared with standard antipsychotic medications, xanomeline/trospium is associated with less:
1. 1. Weight gain
  2. Constipation
  3. Hypertension
Which of the following patients would be the best candidate for treatment with xanomeline/trospium?
1. 1. A patient with newly diagnosed schizophrenia who has never been treated with an antipsychotic.
  2. A patient with schizophrenia who has developed significant movement-related adverse effects during treatment with risperidone.
  3. A patient with schizophrenia who prefers treatment with long-acting injectable medications due to problems remembering to take oral medications.
The mechanism of action of dextromethorphan is different from other medications used to manage depression because it antagonizes which receptor type?
1. 1. Serotonin
  2. NMDA
  3. Glutamate
Which of the following is a common adverse effect associated with dextromethorphan/bupropion?
1. 1. Dizziness
  2. Sexual dysfunction
  3. Weight gain
Which of the following patients would be the best candidate for treatment with dextromethorphan/bupropion?
1. 1. A patient with major depressive disorder and epilepsy who was previously treated with fluoxetine.
  2. A patient with major depressive disorder who has had seven previous antidepressant trials that were not effective.
  3. A patient with major depressive disorder and diabetes mellitus type 2 who has had previous trials with escitalopram and venlafaxine.

Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World-RECORDED WEBINAR

Upon completion of this application based CE Activity, a pharmacist will be able to:

Describe the reasons seniors are increasingly diagnosing and treating themselves with therapies

Describe the legal and regulatory pathways that provide seniors access to therapies outside the drug supply chain

Describe the ways that pharmacists can recommend dietary supplements that are free of adulterants and contaminants

Describe the risks associated with self-treatment with dietary supplements, “peptides”, and counterfeit drug

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-044-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Pharmacist Post Test

Don is a 72-year-old who is looking online for alternatives to self-manage his pain. His prescriber told him he would not write any other prescriptions for oxycodone with APAP. He is looking at kratom and for Canadian Pharmacies that don’t require a prescription. Which of the following is the motivator for Don to transcend the normal medication supply chain?

Cost of prescription options
Circumvent prescriber gatekeeping restrictions
Embarrassment over his health issue

You are a pharmacist at a community pharmacy and a patient asks you which supplements to buy. What is a validated way to assure the dietary supplement you recommend does not have excessive microbial or heavy metal contamination and has the ingredients in the tablets/capsules advertised on the label?

USP certification
Better Homes and Gardens Certification
The most expensive one

Sylvia is a 68-year-old woman who weighs 120 pounds but wants to weigh 108 pounds like she did when she was 40 years old. Which of the following is a good counseling point if she reveals she is using a “peptide” GLP-1 product?

Her obesity is a disorder that requires a GLP-1 product, so the benefits outweigh the risks
These products are known to contain lead and arsenic in too high a level
The labeled dose could vary, and she could overdose or underdose as a result

Don from question 1 finds a “pharmacy” willing to sell him oxycodone with APAP for $7 a pill without a prescription. The site says it is a best seller in Canada. What is the main risk of Don getting his opioids from the unlicensed online site?

Fentanyl adulteration and dose variability could lead to respiratory depression
It is more expensive than the brand name prescription version he now takes
The company offers no certificate of analysis or money back guarantee

A company says its melatonin supplement can “support a restful sleep” and that “this product is not intended to diagnose, evaluate, or treat any disease.” What would the FDA call this?

A legitimate health claim
A legitimate quasi health claim
A legitimate semi-health claim

A woman calls a company that sells “Energy Macha” to complain that her newborn has an extra arm with seven fingers. How long does the company have to alert the FDA about this serious potential adverse event?

1-day
5-days
15-days

Which of the following common adulterants is matched with the type of dietary supplement it is associated with?

Weight Loss – human growth hormone
Muscle Building – sildenafil
Sexual Enhancement – tadalafil

What is the name of the law that controls FDA authority over dietary supplements?

DSHEA 1994
OBRA 1990
FDCA 1927

Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing -RECORDED WEBINAR

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs) for completing the activity ACPE UAN 0009-0000-24-045-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Learning Objectives
• Review the role of the Beers Criteria in reducing potentially inappropriate medication (PIM) use and enhancing patient safety in older adults
• Identify recent updates to the Beers Criteria and their implications for medication management in geriatric care
• Apply the updated Beers Criteria to real-world scenarios, optimizing medication selection and minimizing risks in older adults

1. About how many older adults are prescribed potentially inappropriate medications?
A. One in seven
B. One in five
C. One in three

2. Which of the following describes how age-related physiologic changes affect older adults?
A. Decreased renal and hepatic blood flow slows drug excretion, causing toxicity
B. Frailty increases activity in drug metabolizing pathways, making drugs less effective
C. Decreased body fat and dehydration affect drug distribution and cause toxicity

3. Which of the following best describes a potentially inappropriate medication?
A. A drug that is contraindicated in patients older than 65 years
B. A drug for which risks outweigh benefits in older adults
C. A drug that should only be used in hospice or end-of-life care

4. Which of the following is TRUE?
A. Older adults should always avoid SGLT2 inhibitors
B. The updated criteria removes doxepin < 6 mg/day C. Dabigatran is the safest anticoagulant for older adults 5. Which of the following best describes Beers Criteria guidance on proton pump inhibitors (PPIs)? A. Deprescribe after 8 weeks of scheduled use, unless the patient is high-risk B. After 8 weeks of scheduled use, reevaluate risks and benefits and continue if tolerated C. Avoid scheduled use completely and advise patients to use intermittent antacids 6. Which of the following is a reason to deprescribe a medication found on the Beers Criteria? A. The drug is being used to treat cancer but carries a risk of acid reflux B. The drug is being used to treat two indications at once C. The drug was prescribed to address the adverse effect of another drug 7. Mrs. Taylor, a 78-year-old woman with a history of AFib and diabetes, is prescribed rivaroxaban for stroke prevention and glyburide for glycemic control. During a consultation, she reports episodes of dizziness and has a recent lab result showing a creatinine clearance of 35 mL/min. Which of the following is the BEST plan of action? A. Recommend switching glyburide to glipizide B. Advise switching rivaroxaban to warfarin C. Continue both medications with increased monitoring for AEs

Doppelgangers, Imposters, and New Kids on the Block

REGISTRATION LINK

Accreditation Statements

Disclosure of Discussions of Off-label and Investigational Drug Use

Faculty

Faculty Disclosure

Handouts

SCHEDULE/TOPICS/LEARNING OBJECTIVES

Download Event Brochure

REGISTRATION LINK

Learning Objectives

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Posttest

Learning Objectives

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Posttest

About this Course

Learning Objectives

Additional Information

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Post Test

About this Course

Learning Objectives

Additional Information

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Post Test

About this Course

Learning Objectives

Additional Information

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Post Test

About this Course

Learning Objectives

Additional Information

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer

Content

Handouts

Post Test

About this Course

Learning Objectives

Additional Information

Accreditation Statement

Grant Funding

Faculty

Faculty Disclosure

Disclaimer